David S. Young

Cardiac Dimensions, Inc. develops novel interventional tools for the treatment of heart failure and the related condition of mitral valve regurgitation. It offers the CARILLON Mitral Contour System, a proprietary and implantable device designed to be positioned in the coronary sinus vein using cardiac catheterization techniques. The firm also offers patient enrollment, clinical testing, and medical consulting services. The company was founded by James W. Fitzsimmons and Scott Jordan Wolf in 2001 and is headquartered in Kirkland, WA.

enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada.

Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto.

MedInnova Partners, Inc is a venture capital firm, founded in 2000. The firm headquartered in Halifax, Nova Scotia.

Resonant Medical Inc. develops, manufactures and distributes 3D ultrasound image-guided adaptive radiotherapy products. The company was founded by Fred Francis, Tony Falco and Luc Sirois and is headquartered in Montréal, CA.

U-Systems, Inc. designs, develops, manufactures and markets ultrasound systems. The company was founded in 1997 and is headquartered in Schenectady, NY.

American Diabetes Association provides diabetes related medical services. It funds research, publishes scientific findings, provides information and other services to people with diabetes, their families, health professionals and the public. The company was founded in 1940 and is headquartered in Alexandria, VA.

Sankyo Agro Co., Ltd. operates agricultural chemicals stores. It distributes pesticide and other related products. The company is headquartered in Tokyo, Japan.

The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research.

American Society of Hematology provides the most current practice tools, clinical support and educational products needed in hematology. The firm offers educational products and services for clinicians and scientists. The company is headquartered in Washington, DC.

Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA

Réseau Capital operates as a venture capital and private equity association. It promotes private equity industry in Quebec through training, information and promotion, networking, and representation. The company was founded by Jean-Pierre Chartrand in 1989 and is headquartered in Montréal, Canada.

Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia.

Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA.

QUE Oncology, Inc. engages in preventing and treating life-threatening cancers such as prostate cancer, breast cancer, melanoma, and cancer pain; and related conditions. The company is headquartered in Atlanta, GA.

Gladius Pharmaceuticals, Inc. operates as a biotechnology company. It develops novel drugs to treat multi-drug-resistant bacterial infections. The company was founded by Larry D. Sutton and is headquartered in Montréal, Quebec.

Gladius Pharmaceuticals Corp. operates as a biotechnology firm. The company is headquartered in Wilmington, DE.

Revitope Oncology, Inc. develops a programmable antibody circuit pipeline in particular redirecting T cells to tumors. The company was founded by Andrew Allen and Mark Cobbold and is headquartered in Cambridge, MA.

Remiges Ventures Inc. (Remiges Ventures) is a venture capital firm founded in 2014 by Taro Inaba. It is headquartered in Cambridge, United States.

Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.

Part of Opsens, Inc., Opsens Medical is a Canadian company focused on improving cardiovascular disease diagnosis and treatment. The company is based in Quebec, Canada. Established in 2003, the company believes in the power of innovative technologies to find solutions to challenges and unmet needs in various markets. Opsens Medical capitalizes on its expertise in coronary physiology to extend its activities to the fast-growing sector of structural cardiology.

OsteoqQC, Inc. develops drugs for the treatment of bone-related diseases. The company was founded by Debra Ellies and is headquartered in Montreal, Canada.

Leading Biosciences, Inc. provides healthcare services. It offers therapy for severe sepsis, septic shock, and multi-organ failure. The company was founded by John Rodenrys and is headquartered in Carlsbad, CA.

TOLREMO therapeutics AG engages in discovering and developing therapies for treating cancer patients. The firm serves on academic research laboratories, flourishing life sciences spin-offs and cutting-edge technology platforms. The company was founded by Stefanie Flückiger-Mangual, Wilhelm Krek, Karl-Heinz Altmann, Isaac Kobrin, and Emmanuel Savioz in March 2017 and is headquartered in Zurich, Switzerland.

Actym Therapeutics, Inc. engages in development of novel immuno-oncology therapies. The company was founded by Christopher D. Thanos and Laura Hix Glickman and is headquartered in Berkeley, CA.

Transposon Therapeutics, Inc. provides pharmaceutical products. The company is headquartered in Westport, CT.

Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead.

MycRx is an Australian company that focuses on improving the lives of people with cancer through direct myc inhibitors. The company's main area of expertise is the science of myc inhibition as a treatment for cancer.